Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Atossa Therapeutics, Inc.

Market Cap 15.76M 13.84M 12.75M 11.94M 22.38M 1.49B 22.78M 153M 59.24M 732M 59.16M 57.88M 2.55B P/E 2026 *
-0.42x
P/E 2027 * -0.53x
Enterprise Value 15.76M 13.84M 12.75M 11.94M 22.38M 1.49B 22.78M 153M 59.24M 732M 59.16M 57.88M 2.55B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.29%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+3.83%
1 week-19.15%
Current month-63.67%
1 month-61.69%
3 months-64.35%
6 months-82.34%
Current year-78.53%
1 week 1.78
Extreme 1.78
2.21
1 month 1.78
Extreme 1.78
5.3
Current year 1.78
Extreme 1.78
10.95
1 year 1.78
Extreme 1.78
19.35
3 years 1.78
Extreme 1.78
34.65
5 years 1.78
Extreme 1.78
147
10 years 1.78
Extreme 1.78
891
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
12/05
Ensisheim Partners LLC
OtherCompany 0 0%
12/05Free

Director

10,000 0.1161%
12/05Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
+3.83%-19.15%-83.97%-86.10% 15.76M
+2.96%+4.08%-8.03%-2.24% 43.24B
+2.23%+5.90%+327.41%+578.85% 35.25B
+1.59%+2.96%+11.76%+48.53% 30.22B
+2.07%-3.99%+10.70%-19.82% 28.01B
-4.75%-8.29%+3.90%+13.88% 24.08B
+4.64%+6.85% - - 14.16B
+3.91%+1.28%+53.05%+110.81% 13.01B
+2.77%+2.93%+9.65%+11.90% 12.7B
+0.13%+2.74%+103.13%+84.44% 12.54B
Average +1.94%-2.92%+47.51%+82.25% 21.32B
Weighted average by Cap. +1.65%-0.72%+70.57%+121.59%

Financials

2026 *2027 *
Net sales - -
Net income -37.39M -32.85M -30.26M -28.33M -53.11M -3.54B -54.06M -364M -141M -1.74B -140M -137M -6.04B -39.31M -34.54M -31.82M -29.78M -55.84M -3.72B -56.84M -382M -148M -1.83B -148M -144M -6.35B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
23/06/26 USD 1.900 +3.83% 534,686
22/06/26 USD 1.830 -8.96% 469,933
18/06/26 USD 2.010 +1.26% 193,503
17/06/26 USD 1.985 -10.59% 696,590
16/06/26 USD 2.220 -5.53% 310,191
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.830USD
Average target price
22.00USD
Spread / Average Target
+1,102.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!